Oryzon Genomics S.A. (FRA:ORN)

Germany flag Germany · Delayed Price · Currency is EUR
3.135
+0.025 (0.80%)
At close: Dec 4, 2025
105.44%
Market Cap 252.33M
Revenue (ttm) 7.36M
Net Income (ttm) -2.76M
Shares Out n/a
EPS (ttm) -0.04
PE Ratio n/a
Forward PE 246.44
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume n/a
Open 3.135
Previous Close 3.110
Day's Range 3.135 - 3.135
52-Week Range 1.378 - 3.975
Beta n/a
RSI 50.17
Earnings Date Feb 27, 2026

About Oryzon Genomics

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system) disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2000
Employees 47
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol ORN
Full Company Profile

Financial Performance

In 2024, Oryzon Genomics's revenue was $7.62 million, a decrease of -51.43% compared to the previous year's $15.69 million. Losses were -$3.79 million, 2.39% more than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.